title: A new biocompatible delivery scaffold containing heparin and bone morphogenetic protein 2.
abstract: Silicon-substituted calcium phosphate (Si-CaP) was developed in our laboratory as a biomaterial for delivery in bone tissue engineering. It was fabricated as a 3D-construct of scaffolds using chitosan-trisodium polyphosphate (TPP) cross-linked networks. In this study, heparin was covalently bonded to the residual -NH2 groups of chitosan on the scaffold applying carbodiimide chemistry. Bonded heparin was not leached away from scaffold surfaces upon vigorous washing or extended storage. Recombinant human bone morphogenetic protein 2 (rhBMP-2) was bound to conjugated scaffolds by ionic interactions between the negatively charged SO42- clusters of heparin and positively charged amino acids of rhBMP-2. The resulting scaffolds were inspected for bone regenerative capacity by subcutaneous implanting in rats. Histological observation and mineralization assay were performed after 4 weeks of implantation. Results from both in vitro and in vivo experiments suggest the potential of the developed scaffolds for bone tissue engineering applications in the future.
authors.forename: Suphannee
authors.initials: S
authors.lastname: Thanyaphoo
authors.forename: Jasadee
authors.initials: J
authors.lastname: Kaewsrichan
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D001861:Bone Regeneration / Q000187:drug effects*; D002130:Calcium Phosphates / Q000009:adverse effects / Q000737:chemistry; D048271:Chitosan / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism; D020099:Coated Materials, Biocompatible / Q000009:adverse effects / Q000737:chemistry*; D003432:Cross-Linking Reagents / Q000737:chemistry; D016503:Drug Delivery Systems / Q000009:adverse effects; D065546:Drug Liberation; D005022:Ethyldimethylaminopropyl Carbodiimide / Q000737:chemistry; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D008297:Male; D011122:Polyphosphates / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D012828:Silicones / Q000009:adverse effects / Q000737:chemistry; D012995:Solubility; D013499:Surface Properties; D054457:Tissue Scaffolds / Q000009:adverse effects / Q000737:chemistry*
chemical_list: D000925:Anticoagulants; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D020099:Coated Materials, Biocompatible; D003432:Cross-Linking Reagents; D011122:Polyphosphates; D011994:Recombinant Proteins; D012828:Silicones; D006493:Heparin; D048271:Chitosan; C020243:calcium phosphate; D005022:Ethyldimethylaminopropyl Carbodiimide